Analysis of prostrate-specific immunity in stage III and IV prostate cancer patients
- Conditions
- 10038597prostate cancer
- Registration Number
- NL-OMON32487
- Lead Sponsor
- KI-AV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
• Histologically or cytologically proven stage III or IV prostate carcinoma
• Age above 18 years
• PSA increase and/or CT/MRI confirmed progressive disease under antiandrogen treatment (including LH-RH analogues)
• Performance score: WHO 0,1 or 2 at the time of study entry
• Written informed consent
Exclusion Criteria
• Concurrent treatment with immunosuppressive drugs incl. corticosteroids
• Undergoing any treatment other than antiandrogen therapy
• Severe anemia (Hb < 6.0 mmol/L)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method